Het Imeldaziekenhuis is een middelgroot regionaal, katholiek ziekenhuis in Bonheiden. Het ziekenhuis is vernoemd naar de zalige Imelda Lambertini.

During the past decade, Imelda Ziekenhuis conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 44 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 56 clinical trials started and 28 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Imelda Ziekenhuis" #1 sponsor was "Flanders Medical Research Program" with 24 trials, followed by "Universitaire Ziekenhuizen KU Leuven" with 16 trials sponsored, "Hoffmann-La Roche" with 12 trials sponsored, "ID3 Medical" with 9 trials sponsored and "University Hospital, Ghent" with 9 trials sponsored. Other sponsors include 138 different institutions and companies that sponsored additional 96 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Imelda Ziekenhuis" #1 collaborator was "AZ Sint-Jan AV" with 5 trials as a collaborator, "Imelda Hospital, Bonheiden" with 5 trials as a collaborator, "University Hospital, Antwerp" with 5 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator. Other collaborators include 103 different institutions and companies that were collaborators in the rest 96 trials.

According to Clinical.Site data, the most researched conditions in "Imelda Ziekenhuis" are "Peripheral Arterial Disease" (24 trials), "Ulcerative Colitis" (13 trials), "Coronary Artery Disease" (12 trials), "Crohn's Disease" (11 trials) and "Peripheral Vascular Disease" (10 trials). Many other conditions were trialed in "Imelda Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Imelda Ziekenhuis" are "Drug" (93 trials), "Device" (80 trials), "Other" (19 trials), "Procedure" (19 trials) and "Biological" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (34 trials), "Bevacizumab" (5 trials), "Paclitaxel" (5 trials), "Azithromycin" (3 trials) and "Etrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Imelda Ziekenhuis" are 191 trials for "All" genders, 19 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 61 active trials in "Imelda Ziekenhuis". 1 are not yet recruiting, 34 are recruiting, 23 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 118 completed trials in Imelda Ziekenhuis, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Imelda Ziekenhuis, 1 "Phase 1" clinical trials were conducted, 37 "Phase 2" clinical trials and 61 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 26 trials, and there were also 56 trials that are defined as “Not Applicable".